이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CureVac 관리

관리 기준 확인 2/4

CureVac's CEO는 Alexander Zehnder, Apr2023 에 임명되었습니다 의 임기는 1.17 년입니다. 총 연간 보상은 € 978.33K, 51.1% 로 구성됩니다. 51.1% 급여 및 48.9% 보너스(회사 주식 및 옵션 포함). 는 $ 183.20K 가치에 해당하는 회사 주식의 0.025% 직접 소유합니다. 183.20K. 경영진과 이사회의 평균 재임 기간은 각각 1.4 년과 8.3 년입니다.

주요 정보

Alexander Zehnder

최고 경영자

€978.3k

총 보상

CEO 급여 비율	51.1%
CEO 임기	1.2yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	8.3yrs

최근 관리 업데이트

Recent updates

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02

How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Mar 03

CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma

Feb 04

Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Jan 27

CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates

Jan 11

CEO 보상 분석

Alexander Zehnder 의 보수는 CureVac 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-€273m
Dec 31 2023	€978k	€500k	-€260m

보상 대 시장: Alexander 의 총 보상 ($USD 1.05M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.43M ).

보상과 수익: Alexander 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Alexander Zehnder (54 yo)

1.2yrs

테뉴어

€978,331

보상

Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...

리더십 팀

이름	위치	테뉴어	보상	소유권
Alexander Zehnder	CEO, MD & Member of Management Board	1.2yrs	€978.33k	0.025% € 191.6k
Pierre Kemula	MD, CFO & Member of Management Board	7.7yrs	€654.18k	0.035% € 268.7k
Malte Greune	COO, Member of Management Board & MD	2.9yrs	€600.74k	0.0038% € 29.0k
Myriam Mendila	Chief Scientific Officer	1.4yrs	€614.49k	0.0021% € 16.2k
Ulrike Gnad-Vogt	Senior VP & Area Head of Oncology	1.4yrs	€284.15k	0% € 0
Sarah Fakih	Vice President Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Marco Rau	General Counsel	no data	데이터 없음	데이터 없음
Thorsten Schuller	Head of Corporate Communications	no data	데이터 없음	데이터 없음
Slavica Stevanovic-Heck	Head of Human Resources	no data	데이터 없음	데이터 없음
Patrick Baumhof	Senior Vice President of Technology	no data	데이터 없음	데이터 없음
Ronald Plasterk	Senior Vice President of Science & Innovation	no data	데이터 없음	데이터 없음
Marcus Dalton	Head of Intellectual Property	no data	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: CVAC 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hans-Georg Rammensee	Scientific Director of Immunology and Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Craig Tooman	Supervisory Board Member	5yrs	€96.25k	0.0043% € 32.8k
Karim Fizazi	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Michael Brosnan	Independent Director of Supervisory Board	less than a year	€51.03k	0.0019% € 14.3k
Baron Stephenne	Independent Chairman of Supervisory Board	8.8yrs	€123.75k	0.0075% € 57.0k
Nina Bhardwaj	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Stanley Plotkin	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Michael Manns	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Jean-Paul Prieels	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Mathias Hothum	Supervisory Board Member	8.8yrs	€96.25k	0.0048% € 36.9k
Dirk Jäger	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Christopher Karp	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음

8.3yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: CVAC 의 이사회는 경험(평균 재직 기간 8.3 년)으로 간주됩니다.

CureVac 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. Announces Executive Changes

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces CEO Changes

Recent updates

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 29%, EPS upgraded

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Consensus revenue estimates increase by 57%

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Consensus revenue estimates decrease by 42%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

Now 31% undervalued

CureVac N.V. Announces CEO Changes

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CureVac Announces Executive Changes

CureVac BV reports Q2 results

Consensus estimates of losses per share improve by 10%

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Insider notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 36%

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac: Wait For Concrete News Before Investing

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic